News
NUZTF
0.110
NaN%
--
Neurizon says NUZ-001 preclinical data supports multi-pathway protein clearance in ALS models
Reuters · 3d ago
Neurizon Doses First Patient With NUZ-001 in HEALEY ALS Platform Trial Regimen I
Reuters · 02/26 20:35
FDA CLEARS NUZ-001 FOR ENTRY INTO HEALEY ALS PLATFORM TRIAL
Reuters · 12/11/2025 20:50
FDA Clears Neurizon Therapeutics' NUZ-001 for HEALEY ALS Platform Trial
Reuters · 12/11/2025 20:50
Elanco Executive Justine Conway Appointed as Neurizon Therapeutics Board Observer
Reuters · 11/26/2025 23:17
Elanco in licensing pact with Australia’s Neurizon
Seeking Alpha · 07/03/2025 11:40
More
Webull provides a variety of real-time NUZTF stock news. You can receive the latest news about Neurizon Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About NUZTF
Neurizon Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is engaged in advancing treatments for neurodegenerative diseases. It is developing its lead drug candidate, NUZ-001, for the treatment of Amyotrophic Lateral Sclerosis (ALS), which is the common form of motor neurone disease. ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. ALS is a devastating neurodegenerative condition that primarily affects nerve cells that control voluntary muscles. Through international collaborations and rigorous clinical programs, it is focused on creating new horizons for patients and families impacted by complex neural disorders.